The effect of aromatase inhibitors against possible testis toxicity in pembrolizumab treated rats

dc.contributor.authorTurkmen, Nese Basak
dc.contributor.authorCiftci, Osman
dc.contributor.authorTaslidere, Asli
dc.contributor.authorAydin, Muhterem
dc.contributor.authorEke, Binay Can
dc.date.accessioned2026-08-12T17:20:24Z
dc.date.issued2022
dc.departmentFırat Üniversitesi
dc.description.abstractPembrolizumab is a monoclonal antibody. Anastrozole is an infertility inhibitor of aromatase. Resveratrol is an antioxidant polyphenol in the reproductive system. This study was planned to demonstrate the protective effects of anastrozole and resveratrol against pembrolizumab-induced reproductive damage. Forty-two Sprague-Dawley rats were used in the study. Groups: The control, Pembrolizumab (PEMB), PEMB + Anastrazol (ANAST), PEMB + Resveratrol (RES), RES, and ANAST groups. At the end of the experiment, rats were euthanased under anaesthesia. Tissue samples were taken from rats for biochemical, histological, and ELISA evaluations. Tissues were subjected to routine tissue follow-up for histological analysis. Biochemically, thiobarbituric acid reactive substance (TBARS), glutathione (GSH), catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) levels were measured. Sperm motility, abnormal sperm rate, and epididymal sperm concentration were examined spermatologically. Serum testosterone and programmed cell death-1 (PD-1) levels were measured using the ELISA. TBARS levels were significantly increased and GSH, SOD, GPx, and CAT levels were mitigated in PEMB-treated rats. Histologically; Control, ANAST, and RES groups testis samples were observed with normal histological appearance. Histological damage was detected in seminiferous tubule structures in testicular tissue in the PEMB group. In treatment groups, this damage was decreased. In addition, PD-1 and testosterone levels were evaluated by the ELISA method. ANAST and RES have therapeutic effects against reproductive damage caused by PEMB.
dc.identifier.doi10.1111/and.14557
dc.identifier.issn0303-4569
dc.identifier.issn1439-0272
dc.identifier.issue10
dc.identifier.orcid0000-0003-3902-3210
dc.identifier.orcid0000-0001-5755-3560
dc.identifier.pmid36177829
dc.identifier.scopus2-s2.0-85135850610
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1111/and.14557
dc.identifier.urihttps://hdl.handle.net/11508/53551
dc.identifier.volume54
dc.identifier.wosWOS:000851523600001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofAndrologia
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260511
dc.subjectanastrozole
dc.subjectpembrolizumab
dc.subjectresveratrol
dc.subjecttestis
dc.titleThe effect of aromatase inhibitors against possible testis toxicity in pembrolizumab treated rats
dc.typeArticle

Dosyalar